Current Headlines

  1. Genomics Launches The Mystra AI Platform, Adopted By Industry Giants And Up-And-Coming Biotechs 6/2/2026

    Genomics, a science-led Techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has today announced the launch of Mystra AI, the best-in-class human genetics agentic AI platform designed to supercharge drug target discovery and validation.

  2. Launch Of TechBio Firm, Lucera, Brings Decision Intelligence To Drug Development, Making It More Predictable, More Evidence-Grounded, And More Efficient 6/2/2026

    Lucera GmbH, a TechBio company utilizing its proprietary technology to transform pharmaceutical R&D and enhance development efficacy and efficiency through unique decision intelligence, today announced the launch of its operations.

  3. Sanofi Chooses Snowflake To Accelerate Its AI-Powered Drug Development 6/2/2026

    SNOWFLAKE SUMMIT 26 – Snowflake, the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit.

  4. PolyPid Completes New Drug Application Submission To FDA For D-PLEX₁₀₀ 6/1/2026

    PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the successful completion of its New Drug Application (“NDA”) submission on a rolling review basis to the U.S. Food and Drug Administration (“FDA”) for D-PLEX100, the Company’s lead product candidate for the prevention of surgical site infections (“SSIs”) in patients undergoing colorectal surgery.

  5. China's Original Innovative Drug Cipepofol Approved For Marketing By The U.S. FDA 6/1/2026

    Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the U.S. Food and Drug Administration (FDA), becoming the first China-originated innovative intravenous anesthetic to enter the global market.

  6. Introducing Evosep Proteomics To Standardize And Scale Proteomics For Research And Drug Development 6/1/2026

    Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development.

  7. Zydus Therapeutics New Drug Application (NDA) For Saroglitazar To Treat Primary Biliary Cholangitis (PBC) Granted Priority Review By The US FDA 5/28/2026

    Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation-led health care company, today announced that the US Food and Drug Administration (US FDA) granted Priority Review to the New Drug Application (NDA) for saroglitazar.

  8. Quotient Sciences Advances AI-Designed Drug Product Into Clinical Development 5/28/2026

    Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) - a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development.

  9. From Hit Identification To Lead Optimization: Building Scientific Continuity In Early Drug Discovery 5/27/2026

    On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry."

  10. Momentum Biotechnologies Launches CHIPP, A Novel High-Throughput Target Deconvolution Technology 5/27/2026

    Momentum Biotechnologies ("Momentum"), a contract research organization that leverages mass spectrometry for drug discovery, announced today the launch of CHIPP (chaotrope-induced protein precipitation and proteome profiling), a novel, sensitive, scalable, and label-free assay for the analysis of drug:target interactions.